Bellerophon Therapeutics (BLPH) 10-Q2023 Q2 Quarterly report

Filed: 14 Aug 23, 4:30pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: attract, attractive, belief, bid, Bulletin, compliance, conclusion, consummate, consummated, coverage, decision, deficit, delisted, delisting, Department, desirable, discretion, dispose, dissolution, employment, exploration, explore, exploring, flexible, healthcare, hearing, heavily, infusion, light, listed, listing, lose, maximize, maximizing, merger, minimal, Nasdaq, national, notified, opening, ordinary, OTC, Panel, private, projected, recent, recently, regain, remote, remotely, rent, request, requested, Rule, scheduled, secondary, shareholder, shell, timetable, unknown, winding, workforce, workspace

Removed: approximating, assessing, assessment, biotechnology, calculate, calculating, closely, collaborative, Committee, comparable, competing, continued, criteria, delay, delayed, deployed, eligibility, enter, fewer, fluctuate, history, incur, independent, inherent, interrupted, invest, labeling, leave, manner, meeting, pandemic, positioned, predicted, prefer, recruit, represent, senior, serve, spread, thromboembolic, track, transitioned, unprofitable, unrelated

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

BLPH similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of Bellerophon Therapeutics, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer's knowledge, that:

(1) the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 14, 2023

By:

/s/ Peter Fernandes

Peter Fernandes

Chief Executive Officer

(Principal Executive Officer and

Principal Financial and Accounting Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.